Impact of Brokerage Rating on Synthetic Biologics, Inc(SYN)

Many Synthetic Biologics, Inc(SYN) Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock. Company shares were Reiterated by FBR & Co. on Jan 6, 2017 to Outperform, Raises Price Target to $ 6 from a previous price target of $5 .

Synthetic Biologics, Inc (NYSEMKT:SYN) has received a short term rating of buy from experts at Zacks with a rank of 2. The stock has been rated an average of 1 by 3 Brokerage Firm. 3 Wall Street Firms have rated the stock as a strong buys.

Synthetic Biologics, Inc (NYSEMKT:SYN): The stock price is expected to reach $ 5.33 in the short term. The number of analysts agreeing with this consensus is 3. The higher estimate for the short term price target is at $7 while the lower estimate is at $3. The standard deviation of the price stands at $2.08.

Synthetic Biologics, Inc (NYSEMKT:SYN) witnessed a decline in the market cap on Tuesday as its shares dropped 3.26% or 0.0277 points. After the session commenced at $0.85, the stock reached the higher end at $0.8549 while it hit a low of $0.82. With the volume soaring to 678,701 shares, the last trade was called at $0.8223. The company has a 52-week high of $2.735. The company has a market cap of $96 million and there are 117,172,714 shares in outstanding. The 52-week low of the share price is $0.7349.

Synthetic Biologics, Inc. is a biotechnology company focused on the development of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses. The Company is engaged in developing product candidates to treat pulmonary arterial hypertension, relapses in multiple sclerosis, cognitive dysfunction in multiple sclerosis, fibromyalgia and amyotrophic lateral sclerosis. Synthetic Biologics, Inc., formerly known as Adeona Pharmaceuticals, Inc., is headquartered in Ann Arbor, Michigan.

Synthetic

Share this post

Leave a Reply